Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma
- 526 Downloads
Oral mucositis is one of the most painful side effects found in esophageal squamous cell carcinoma (ESCC) patients treated with chemoradiotherapy. The transdermal route of administration is worthy of investigation for patients who suffer from dysphagia due to severe oral mucositis. In this phase 2 study, we investigated the efficacy and safety of transdermal fentanyl (TDF) for mucositis pain caused by chemoradiotherapy in ESCC patients.
Forty-six ESCC patients who experienced moderate to severe oral mucosal pain during chemoradiotherapy received TDF for pain relief. The assessment of pain was made according to the Numeric Rating Scale (NRS). Efficacy and safety of TDF was collected and conducted in an open-label fashion. The analgesic effect, quality of life, and side effects were evaluated after the administration of transdermal fentanyl using the paired sample Wilcoxon signed rank test.
The mucositis-induced pain disappeared in 31 (67.4 %) patients during the treatment with transdermal fentanyl with the median time of onset at day 6.6 (range 3–14). The median Numeric Rating Scale (NRS) score was reduced from 6 (range 3–9) before treatment to 4.5 (range 2–9), 3 (range 2–8), 2.5 (range 1–8), 2 (range 0–6), and 0 (range 0–4) on days 3, 6, 9, 11, and 15, respectively, after treatment (P < 0.001). The patients’ quality of life also improved significantly (P < 0.01). The side effects of treatment were mild and disappeared within several days.
Transdermal fentanyl is an effective, convenient, and well-tolerated treatment for mucositis pain caused by chemoradiotherapy, which can improve ESCC patients’ quality of life.
KeywordsEsophageal squamous cell carcinoma Transdermal fentanyl Chemoradiotherapy Oral mucositis
Conflicts of interest
There are no any actual or potential conflicts of interest that exist.
- 4.Blazeby JM, Brookes S, Griffin SM, Crosby T, Donovan J, Hollingworth W (2014) Quality of life in patients with esophageal squamous cell cancer receiving surgery or definitive chemoradiotherapy: results from a randomized controlled trial. Ann Surg 259(5):e81. doi: 10.1097/SLA.0b013e3182480871 PubMedCrossRefGoogle Scholar
- 5.Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15(3):305–314. doi: 10.1016/S1470-2045(14)70028-2 PubMedCrossRefGoogle Scholar
- 6.van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. doi: 10.1056/NEJMoa1112088 PubMedCrossRefGoogle Scholar
- 8.Yazbeck VY, Villaruz L, Haley M, Socinski MA (2013) Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Cancer J 19(3):231–237. doi: 10.1097/PPO.0b013e31829453fb00130404-201305000-00008 PubMedCrossRefGoogle Scholar
- 9.Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21(1):313–326. doi: 10.1007/s00520-012-1644-z PubMedCrossRefGoogle Scholar
- 12.Saunders DP, Epstein JB, Elad S, Allemano J, Bossi P, van de Wetering MD, Rao NG, Potting C, Cheng KK, Freidank A, Brennan MT, Bowen J, Dennis K, Lalla RV (2013) Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3191–3207. doi: 10.1007/s00520-013-1871-y PubMedCrossRefGoogle Scholar
- 17.Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20(9):1419–1428. doi: 10.1185/030079904X2114 PubMedCrossRefGoogle Scholar
- 21.Demarosi F, Lodi G, Soligo D, Sardella A, Volpe AD, Carrassi A, Deliliers GL (2004) Transdermal fentanyl in HSCT patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant 33(12):1247–1251. doi: 10.1038/sj.bmt.1704515 PubMedCrossRefGoogle Scholar
- 22.Kim JG, Sohn SK, Kim DH, Baek JH, Chae YS, Bae NY, Kim SY, Lee KB (2005) Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation. Transplant Proc 37(10):4488–4491. doi: 10.1016/j.transproceed.2005.11.038 PubMedCrossRefGoogle Scholar
- 27.National Cancer Institute (U.S.) (2009) Common terminology criteria for adverse events (CTCAE). NIH publication, vol no 10–5410, Rev. edn. U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MdGoogle Scholar
- 28.American Psychiatric Association., American Psychiatric Association. Task Force on DSM-IV (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
- 29.Vielvoye-Kerkmeer AP, Mattern C, Uitendaal MP (2000) Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manag 19(3):185–192CrossRefGoogle Scholar
- 32.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRefGoogle Scholar
- 35.Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66(3):253–262PubMedCrossRefGoogle Scholar